Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation
暂无分享,去创建一个
G. Remuzzi | E. Daina | P. Ruggenenti | M. Abbate | M. A. Podestà | Camillo Carrara | P. Rizzo | R. Piras | M. Alberti
[1] G. Remuzzi,et al. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] P. Barlow,et al. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice , 2019, The Journal of clinical investigation.
[3] E. Daugas,et al. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] G. Remuzzi,et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. , 2017, Journal of the American Society of Nephrology : JASN.
[5] S. Arora,et al. Long-term Eculizumab Therapy in a Child With Refractory Immune Complex–Mediated Membranoproliferative Glomerulonephritis , 2017, Kidney international reports.
[6] W. Clark,et al. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases? , 2017, BMJ Case Reports.
[7] G. Remuzzi,et al. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015 , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] V. D’Agati,et al. Pathology after eculizumab in dense deposit disease and C3 GN. , 2012, Journal of the American Society of Nephrology : JASN.
[9] V. D’Agati,et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[10] F. Fervenza,et al. Membranoproliferative glomerulonephritis--a new look at an old entity. , 2012, The New England journal of medicine.
[11] G. Remuzzi,et al. Eculizumab in a patient with dense-deposit disease. , 2012, The New England journal of medicine.
[12] F. Emma,et al. Eculizumab and Refractory Membranoproliferative Glomerulonephritis , 2012 .
[13] V. Frémeaux-Bacchi,et al. C3 glomerulopathy: a new classification , 2010, Nature Reviews Nephrology.
[14] R. Gruppo,et al. Eculizumab for congenital atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.
[15] N. Young,et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.
[16] M. Walport,et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Walport,et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H , 2002, Nature Genetics.
[18] N. Perico,et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. , 1995, Journal of the American Society of Nephrology : JASN.